United Therapeutics Corporation (UTHR) is a publicly traded company in the Healthcare — Biotechnology industry listed on NASDAQ. This overview shows the latest price, key valuation ratios, profitability metrics and financial-health indicators used by fundamental investors.
United Therapeutics Corporation, a biotechnology firm, is dedicated to discovering, developing, and bringing to market medical solutions for individuals suffering from chronic and severe, often life-threatening, illnesses. Its operations span both the United States and international markets.
Is United Therapeutics Corporation stock overvalued or undervalued in 2026?
United Therapeutics Corporation (UTHR) trades at 21.5× earnings (P/E). No valuation verdict: it has no earnings to calculate a P/E from.
Kaplio overview: United Therapeutics Corporation
Market cap $26B · 52 weeks $437 – $599 (0 % below the high) · P/E 21.5× · 2027 expected P/E 19.5× · Dividend none · Next earnings November 4, 2026 · expected EPS $6.01 · Closing price, Oct 30 · accounts published Aug 5.
- Valuation: P/Sales 11.8× (no earnings).
- Balance sheet: Safe zone (solid).
- Earnings: 4 of 8 (uneven).
What would it be worth at its usual multiples?
No valuation verdict: it has no earnings to calculate a P/E from.
What matters in biotech: 2 of 4 pass
- R&D / Market cap 2.1 %, fails.
- Market cap / Cash 17.0×, fails.
- Annual cash burn $35.24, passes.
- Total Debt 0.0×, passes.
Against its peers (reference peers) — United Therapeutics Corporation: P/E 21.4×; EV/EBITDA 14.1×; ROIC 17.7 %; $25.7B. Liquidia Corporation (P/E 32.9×; EV/EBITDA 21.8×; ROIC 46.9 %; $4.0B), Incyte Corporation (P/E 64.0×; EV/EBITDA 24.2×; ROIC 6.0 %; $24.4B), Alnylam Pharmaceuticals, Inc. (P/E 8.3×; EV/EBITDA 18.3×; ROIC 15.4 %; $22.1B).
Profitability
| Return on Equity | 20.18% |
| Return on Invested Capital | 17.69% |
| Return on Assets | 18.16% |
| Gross Margin | 86.14% |
| Operating Margin | 44.49% |
| Net Margin | 41.56% |
Financial Health
| Debt / Equity | 0.00 |
| Current Ratio | 5.73 |
| Piotroski F-Score | 7 |
| Altman Z-Score | 19.56 |
Price Performance
| 1 month | +4.78% |
| 3 months | +15.65% |
| Year-to-date | +22.88% |
| 1 year | +34.41% |
| 3 years | +167.19% |
| 5 years | +209.00% |
| 10 years | +403.38% |
Related companies: INSM · LQDA · TVTX · VRTX · 0QZU.L · REGN · MRNA · 0R2M.L
Explore sector: Healthcare · Biotechnology
More sections of UTHR: Financials · Valuation · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method today · Companies that pass the Lynch method today · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks